key: cord-0902324-eqjhv3o0
authors: Engjom, Hilde; van den Akker, Thomas; Aabakke, Anna; Ayras, Outi; Bloemenkamp, Kitty; Donati, Serena; Cereda, Danilo; Overtoom, Evelien; Knight, Marian
title: Severe COVID-19 in pregnancy is almost exclusively limited to unvaccinated women – time for policies to change
date: 2022-01-26
journal: Lancet Reg Health Eur
DOI: 10.1016/j.lanepe.2022.100313
sha: de46dd4861dfbfea422de85893c3badfdb24e569
doc_id: 902324
cord_uid: eqjhv3o0

nan

Severe COVID-19 in pregnancy is almost exclusively limited to unvaccinated women − time for policies to change Pregnant women continue to be excluded from most clinical trials of COVID-19 vaccines and medication, despite very clear pre-pandemic guidance. 1 There appears little incentive amongst regulators or pharmaceutical companies to change this. Compounded by their exclusion, there is considerable vaccine hesitancy amongst pregnant women. 2 Such hesitancy persists, even though at present adverse outcomes of SARS-CoV-2 infection are increasing among pregnant and postpartum women in many countries, 3 while these are improving in most other groups. The impact of the omicron variant is, as yet, unknown.

Vaccine hesitancy in pregnancy is not a new phenomenon. Salmon and colleagues 4 identified three factors which influence parents' acceptance of vaccines for either them or their children: confidence in the efficacy of the vaccines, trust in their healthcare professionals, and, importantly, certainty of the systems to assess vaccine safety. They note that addressing vaccine hesitancy is a "complex problem [which] requires a multilevel approach, including interventions at the individual and health system levels." Data suggest that vaccines are a highly effective protection against severe COVID-19 in the non-pregnant populations in which they were initially tested. 5 However, in many countries, pregnant and postpartum women and those planning a pregnancy continue to receive conflicting messages, mainly regarding the safety of the vaccines. Misleading information on social media continues to impede uptake of vaccination in pregnant and postpartum women, even though observational data about vaccine safety, now including more than 250 000 women, are very reassuring. 6 Additionally, clear potential benefits have been documented, such as placental transmission of protective antibodies to the fetus. 7 By preventing maternal disease, vaccination may prevent stillbirths, preterm births and associated neonatal deaths.

Simultaneously, it has become clear that pregnant and postpartum women are at higher risk of serious illness compared to their non-pregnant contemporaries. This seems especially true for the Delta variant, which increased the risk of intensive care unit admission among pregnant women 2-3 times, with a 50% increase in iatrogenic preterm births. 3, 8, 9 Several European countries (Norway, UK) have recently recognised pregnant and postpartum women as an 'at risk' priority group for COVID-vaccination. This policy has been in place for even longer in other countries (Belgium, Denmark), yet it is still not universal (for example, in Italy, the Netherlands and Finland pregnant women are not prioritised).

Multiple initiatives to promote uptake of COVID-vaccination in pregnancy have been undertaken, with widely differing uptake rates and uptake estimates varying between 22% in England and 80% in Norway. Surprisingly, data are not available on Covid-19 vaccination rates amongst pregnant women in all European countries. Within the International Network of Obstetric Survey Systems (INOSS) 10 we have been able to combine surveillance data in six countries showing that amongst the most critically ill pregnant and postpartum women, almost none were vaccinated (Table 1) . This is observed despite widely varying population vaccine uptake rates.

Our findings emphasize the message to unvaccinated pregnant women, their partners, health professionals caring for pregnant women, decision makers and politicians that vaccination protects against severe disease. As the world is entering a new phase of the COVID-pandemic, with the Delta-variant rapidly being overtaken by the Omicron-variant, booster vaccinations are increasingly important to provide protection against severe COVID-19, especially in vulnerable groups such as pregnant and postpartum women or women who want to become pregnant. However, large numbers of pregnant and postpartum women in low, middle and high-income settings have yet to receive even a single vaccination dose. Health system as well as individual actions are now clearly needed. The World Health Organisation recommends COVID-19 vaccination in pregnant women when the benefits of vaccination to the pregnant woman outweigh the potential risks. These multi-country data clearly show those benefits in terms of prevention of severe disease. We believe that all governments should now prioritise pregnant and postpartum women as an at-risk group and encourage their vaccination. 

Supplementary material associated with this article can be found in the online version at doi:10.1016/j. lanepe.2022.100313.

Pregnant Women & Vaccines Against Emerging Epidemic Threats: Ethics Guidance for Preparedness, Research, and Response

Countering COVID-19 Vaccine Hesitancy in Pregnancy: the "4 Cs

Impact of SARS-CoV-2 variant on the severity of maternal infection and perinatal outcomes: Data from the UK Obstetric Surveillance System national cohort

Vaccine hesitancy: Causes, consequences, and a call to action

Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis

Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons

Trans-Placental Transfer of SARS-Cov-2 Antibodies in recovered and BNT162b2-vaccinated patients. American journal of obstetrics and gynecology

SARS-CoV-2 infection among hospitalised pregnant women and impact of different viral strains on COVID-19 severity in Italy: a national prospective population-based cohort study

SARS-CoV-2 en zwangerschap in Nederland: registratie tijdens een pandemie door NethOSS

The International Network of Obstetric Survey Systems (INOSS): benefits of multi-country studies of severe and uncommon maternal morbidities

The authors would like to acknowledge the contributions of all reporting clinicians, research and administration teams without whom the INOSS studies would not be possible.